

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED
阿里健康信息技術有限公司
(Incorporated in Bermuda with limited liability)
(Stock code: 00241)

**RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR,
CHAIRMAN OF THE REMUNERATION COMMITTEE AND MEMBER
OF THE AUDIT COMMITTEE**

The board (the “**Board**”) of directors (the “**Directors**”) of Alibaba Health Information Technology Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) announces that with effect from April 8, 2019, Mr. Yan Xuan (“**Mr. Yan**”) has resigned as an independent non-executive Director of the Company in order to avoid any potential conflicts of interest and to devote more time to his new employment in information technology. Upon his resignation, he ceased to be the chairman of the remuneration committee of the Company (the “**Remuneration Committee**”) and a member of the audit committee of the Company (the “**Audit Committee**”).

Mr. Yan has confirmed to the Company that he has no disagreement with the Board and there are no matters that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in respect of his resignation.

Upon resignation of Mr. Yan as an independent non-executive Director, the number of independent non-executive Directors falls below the minimum number required under Rules 3.10(1) and 3.10A of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”). In addition, the number of members of the Audit Committee and the Remuneration Committee fall short of the requirements under Rules 3.21 and 3.25 of the Listing Rules, respectively, and the Company no longer fulfils the requirement of establishing a Remuneration Committee chaired by an independent non-executive director and comprising a majority of independent non-executive directors under Rule 3.25 of the Listing Rules.

With a view to comply with the above requirements under the Listing Rules and the terms of reference of the Audit Committee and the Remuneration Committee, the Company is endeavouring to identify a suitable candidate to fill the above vacancies as soon as practicable and in any event within three months from the effective date of Mr. Yan's resignation. Further announcement will be made by the Company in relation to such appointments as and when appropriate.

The Board would like to take this opportunity to express its appreciation for the valuable contributions made by Mr. Yan to the Company during his tenure of service as an independent non-executive Director.

For and on behalf of the Board
Alibaba Health Information Technology Limited
SHEN Difan
Chief Executive Officer and Executive Director

Hong Kong, April 8, 2019

As at the date of this announcement, the Board comprises seven Directors, of which (i) two are executive Directors, namely Mr. SHEN Difan and Mr. WANG Qiang; (ii) three are non-executive Directors, namely Mr. WU Yongming, Mr. WANG Lei, Ms. ZHANG Yu; and (iii) two are independent non-executive Directors, namely Mr. LUO Tong and Mr. WONG King On, Samuel.